MedPath

The prediction using diffusion-weighted MRI of the response evaluation in borderline resectable/locally advanced pancreatic cancer. in patients undergoing neoadjuvant therapy

Not Applicable
Conditions
Pancreatic carcinoma
Registration Number
JPRN-UMIN000022010
Lead Sponsor
Wakayama Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

1. Without severe drug allergy. 2. With history of malignant disease within 5 years. 3. Active stutus of infectious disease. 4. With metal in body which is contraindication for MRI. 5. With claustrophobia. 6. Incapability to collaborate in respiration. 7. The presensen of uncontrollable ascites.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath